A PDE2 inhibitor such as a 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] -quinoxaline compound and a PDE10 inhibitor for use in the treatment of a neurological or metabolic disorder combination农业专利-农业专业知识服务系统

发明人:: メゲンス，アントニウス，アドリアヌス，ヘンドリクス，ペトラス,ラングロア，ザビエル，ジーン，ミッチェル,ヴァンホーフ，グレタ，コンスタンシア，ピーター,アンドレス－ギル，ホセ，イグナシオ,デアンゲリス，メリ,ブイジュンスターズ，ピーター，ヤコブ，ヨハネス，アントニウス,トラバンコ－スアレツ，アンドレス，アヴェリノ,ロンボウツ、フレデリック，ジャン，リタ,メゲンス,アントニウス,アドリアヌス,ヘンドリクス, ペトラス,ラングロア,ザビエル,ジーン,ミッチェル,ヴァンホーフ,グレタ,コンスタンシア,ピーター,アンドレス-ギル,ホセ,イグナシオ,デアンゲリス,メリ,ブイジュンスターズ,ピーター,ヤコブ,ヨハネス,アントニウス,トラバンコ-スアレツ,アンドレス,アヴェリノ,ロンボウツ、フレデリック,ジャン,リタ

摘要：: The present invention relates to combinations of phosphodiesterase 2 (PDE2) inhibitors with inhibitors of phosphodiesterase 10 (PDE10). In particular, the invention relates to combinations of 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]-quinoxaline derivatives which have been found to inhibit phosphodiesterase 2 (PDE2), with inhibitors of phosphodiesterase 10 (PDE10). Particular PDE10 inhibitors are selected from the group of MP-10, PQ-10, TP-10, papaverine, and the compounds disclosed in WO 2011/051324 and in WO 2011/110545. The invention is also directed to pharmaceutical compositions comprising such combinations, to processes for preparing such compositions, to the use of PDE2 inhibitors, in particular of 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]-quinoxaline derivatives for the potentiation of said PDE10 inhibitors, and to the use of said PDE10 inhibitors for the potentiation of the effect of said PDE2 inhibitors, in particular, 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]-quinoxaline derivatives, and to the use of such combinations and compositions for the prevention and treatment of disorders in which PDE2 and PDE10 are involved, such as neurological and psychiatric disorders, and endocrinological or metabolic diseases.